Anixa Biosciences INC

Anixa Biosciences announced encouraging patient survival data and regulatory approval for dose escalation in its Phase 1 ovarian cancer CAR-T clinical trial.

Anixa Biosciences announced positive final Phase 1 clinical trial data for its investigational breast cancer vaccine, meeting primary endpoints and showing immune response.

Anixa Biosciences successfully held its 2025 annual meeting, resulting in the re-election of directors, approval of executive compensation, and ratification of the accounting firm appointment.

Anixa Biosciences and Cleveland Clinic presented updated positive data from their Phase 1 breast cancer vaccine trial, showing promising immune responses and safety across multiple cohorts.

Anixa Biosciences has entered into a joint development agreement with Cleveland Clinic to develop novel vaccines for various cancer types, expanding their existing collaboration.

Anixa Biosciences successfully held its 2024 annual meeting, re-electing four directors, approving executive compensation on an advisory basis, and ratifying its independent auditor.

Anixa Biosciences reports a net loss of $2.5 million for the second quarter of 2026 while continuing clinical development of its oncology pipeline.

Anixa Biosciences' latest 10-Q filing reveals a significant reduction in net loss and operating expenses, alongside promising clinical progress in its cancer vaccine and CAR-T therapy programs.

Anixa Biosciences, a biotechnology company focused on oncology therapies and vaccines, reported a reduced net loss for the six months ended April 30, 2025, while continuing to advance its CAR-T and breast cancer vaccine clinical programs, despite an increase in cash used in operating activities and a decline in total current assets.

Anixa Biosciences reports its financial results for the first quarter of 2025, highlighting its ongoing efforts in developing cancer vaccines and CAR-T therapeutics.

Anixa Biosciences reported its financial results for the third quarter of 2024, highlighting ongoing clinical trials and research and development activities.

Anixa Biosciences reported its second quarter 2024 results, highlighting progress in its cancer vaccine and therapy programs, while also detailing a new joint development agreement with Cleveland Clinic.

Anixa Biosciences, Inc. reported positive final Phase 1 clinical trial data for its investigational breast cancer vaccine and continued progress in its CAR-T ovarian cancer therapy, despite ongoing net losses and reliance on future funding.

Anixa Biosciences reports its fiscal year 2024 results, showcasing advancements in its cancer vaccine and CAR-T therapy programs despite ongoing losses and reliance on future funding.

Anixa Biosciences' annual report details its financial status and progress in developing cancer vaccines and therapies, while pausing its COVID-19 antiviral program.

Amit Kumar, Chief Executive Officer and a Director of Anixa Biosciences Inc, purchased 5,000 shares of common stock on July 31, 2026 for $3.47 per share.

Arnold M Baskies, a Director of Anixa Biosciences Inc, reported multiple transactions in common stock on July 27, 2026.

Amit Kumar, Chief Executive Officer and a Director of Anixa Biosciences Inc, purchased 5,000 shares of common stock on July 27, 2026 for $3.44 per share.

Amit Kumar, Chief Executive Officer and a Director of Anixa Biosciences Inc, purchased 3,188 shares of common stock on July 27, 2026 for $3.37 per share.

Amit Kumar, Chief Executive Officer and a Director of Anixa Biosciences Inc, purchased 3,000 shares of common stock on July 24, 2026 for $3.73 per share.

Amit Kumar, Chief Executive Officer and a Director of Anixa Biosciences Inc, purchased 5,000 shares of common stock on July 20, 2026 for $3.46 per share.

Anixa Biosciences, Inc. announced its 2026 Annual Meeting of Stockholders to be held virtually on March 10, 2026, to vote on director elections, executive compensation, and auditor ratification.

Anixa Biosciences announces its 2025 Annual Meeting of Stockholders to be held virtually on March 20, 2025, to vote on director elections, executive compensation, auditor ratification, and advisory votes on executive compensation frequency.

Michael Catelani increased his beneficial ownership in Anixa Biosciences, Inc. to 7.0% through market purchases and stock option exercises, including a new grant.

Anixa Biosciences Inc. reports that insider Amit Kumar has increased his beneficial ownership in the company to 16.3% of outstanding common stock, up from 15.1%.

Dr. Amit Kumar, a key insider at Anixa Biosciences Inc., has increased his beneficial ownership in the company to 15.1% of outstanding common stock, primarily driven by new stock option grants and market purchases.